The table below shows Sarepta Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$205.48M
-$205.79M
-$500.99M
-$325.35M
-$443.17M
$107.47M
Capital expenditure
$101.97M
$136.96M
$76.11M
$30.82M
$38.49M
$82.20M
Investing cash flow
$69.64M
$755.56M
-$165.80M
-$1.05B
$495.41M
-$121.72M
Dividends paid
-
-
-
-
-
SRPT operating cash flow (10-K history)
Sarepta Therapeutics, Inc. reported operating cash flow of -$205.48M for fiscal year 2025. That is up 0.1% from -$205.79M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$245.82M (FY 2016) to -$205.48M. Figures come from the company's audited annual reports as filed with the SEC.
